encorAfenib, biNimetinib and Cetuximab in Subjects witH previOusly Untreated BRAF-mutant ColoRectal Cancer

赞助:

合作者:

信息的提供 (责任方):

，

追踪信息

首次提交日期 ^ICMJE

September 17, 2018

首次发布日期e ^ICMJE

October 2, 2018

最后更新发布日期

October 2, 2018

预计研究开始日期 ^ICMJE

October 2018

预计主要完成日期

June 2020 (主要结果测量的最终数据收集日期)

目前主要观察指标 ^ICMJE

Confirmed Overall Response Rate (cORR) based on local tumor assessments[ Time Frame: Duration of the study, approximately 25 months ]

Assessment of tumor evaluation change from baseline

原始主要观察测量 ^ICMJE

与当前相同

目前的二级观察 ^ICMJE

Confirmed Overall Response Rate (cORR) based on central tumor assessment[ Time Frame: globally assessed by subject based on tumor evaluations every 6 weeks for the first 12 weeks and then every 8 weeks. ]
Percentage of subjects with complete response (CR) and partial response (PR)
Overall response (ORR) based on local tumor assessments[ Time Frame: Globally assessed by subject based on tumor evaluations every 6 weeks for the first 12 weeks and then every 8 weeks. ]
Percentage of subjects with complete response (CR) and partial response (PR)
Overall response (ORR) based on central tumor assessments[ Time Frame: Globally assessed by subject based on tumor evaluations every 6 weeks for the first 12 weeks and then every 8 weeks. ]
Percentage of subjects with complete response (CR) and partial response (PR)
Duration of Response (DOR) per local assessment[ Time Frame: Duration of study approximately 25 months ]
Time from first radiographic evidence of response assessed based on local radiologist/investigator review to the earliest documented PD or death due to underlying disease
Duration of Response (DOR) per central assessment[ Time Frame: Duration of study approximately 25 months ]
Time from first radiographic evidence of response review to the earliest documented PD or death due to underlying disease
Time to Response (TTR) per local review[ Time Frame: Duration of study approximately 25 months ]
Time from first dose until first documented radiographic evidence of response of CR or PR
Time to Response (TTR) per central review[ Time Frame: Duration of study approximately 25 months ]
Time from first dose until first documented radiographic evidence of response of CR or PR
Progression of Free Survival (PFS) per local review[ Time Frame: Duration of study approximately 25 months ]
Time from first dose to the earliest documented date of disease progression or death due to any cause
Progression of Free Survival (PFS) per central review[ Time Frame: Duration of study approximately 25 months ]
Time from first dose to the earliest documented date of disease progression or death due to any cause
Overall Survival (OS)[ Time Frame: Duration of study approximately 25 months ]
Time from first dose to death due to any cause
Safety through the incidence of adverse events[ Time Frame: Duration of study approximately 25 months ]
Plasma concentration of encorafenib[ Time Frame: 2 hours and 6 hours after dose on Day 1 cycle 1; Predose and 2 hours post dose on Day 1 cycle 2 (cycle length = 28 days) ]
Plasma concentration of encorafenib
Plasma concentration of binimetinib[ Time Frame: 2 hours and 6 hours after dose on Day 1 cycle 1; Predose and 2 hours post dose on Day 1 cycle 2 (cycle length = 28 days) ]
Plasma concentration of binimetinib
Plasma concentration of cetuximab[ Time Frame: 2 hours and 6 hours after dose on Day 1 cycle 1; Predose and 2 hours post dose on Day 1 cycle 2 (cycle length = 28 days) ]
Plasma concentration of cetuximab
Comparison of Quality of Life from Baseline to end of the study[ Time Frame: At screening, at Cycle 1 Day 1 and at the end of the study (each cycle is 28 days) ]
Change in the Quality of Life Questionnaire for Cancer subjects.

描述性信息

简略标题 ^ICMJE

encorAfenib, biNimetinib and Cetuximab in Subjects witH previOusly Untreated BRAF-mutant ColoRectal Cancer

正式标题 ^ICMJE

Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer

简要概况

The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received any prior treatment for their metastatic disease.

详细说明

The presence of a BRAFV600E mutation is considered a marker of poor prognosis in subjects with mCRC. The preclinical results and preliminary clinical data together justify the evaluation of this triple combination in the first-line setting of this population. The primary objective of the study is to evaluate the antitumor activity of the combination of encorafenib, binimetinib and cetuximab by assessing the overall response rate in adult subjects with previously untreated BRAFV600E-mutant metastatic colorectal cancer. It will also assess the effect of the triple combination on the duration of response, time to response, progression-free survival and overall survival and assess the effect on quality of life. It will also characterize the safety and tolerability of the triple combination as well as describe the pharmacokinetics (PK) of encorafenib, binimetinib, and cetuximab.

研究类型 ^ICMJE

Interventional

研究阶段

Phase 2

研究设计 ^ICMJE

分配:
干预模型: Single Group Assignment
干预模型描述:
盲法: Interventional
盲法描述:All involved know the identity of the intervention assignment.
主要目的: Treatment

适用条件 ^ICMJE

干预项目 ^ICMJE

Drug: encorafenib
Once daily, orally
Drug: Binimetinib
Twice daily, orally
Drug: Cetuximab
Standard of care for the 28 first weeks and then every 2 weeks

研究工具

Experimental: 1 Arm
encorafenib plus binimetinib plus cetuximab

招募信息

招募状态 ^ICMJE

Not yet recruiting

预计入组 ^ICMJE

原始预计入组 ^ICMJE

与当前相同

预计研究完成日期

October 2020

预计主要完成日期

June 2020 (主要结果测量的最终数据收集日期)

合格标准 ^ICMJE

Inclusion Criteria: - Male or female ≥ 18 years of age - Histologically or cytologically confirmed CRC that is metastatic - Presence of BRAF V600E in tumor tissue determined by local assay at any time prior to screening and confirmed by central laboratory - Evidence of measurable disease as per RECIST, v1.1 - Subject able to receive cetuximab as per approved label with regards to RAS status - ECOG Status 0 or 1 - Adequate renal, hepatic, cardiac and bone marrow functions and adequate electrolytes as per protocol - Subject able to take oral medications Exclusion Criteria: - Prior systemic therapy for metastatic disease - Prior treatment with any RAF inhibitor, MEK inhibitor, cetuximab or other anti-EGFR inhibitors - Symptomatic brain metastasis or Leptomeningeal disease - History or current evidence of Retinal Vein Occlusion (RVO) or current risk factors for RVO - History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ≤ 12 months prior to first dose. - Impaired cardiovascular function or clinically significant cardiovascular diseases: history of myocardial infarction or coronary disorders within 6 months prior to start of study treatment, symptomatic congestive heart failure (grade 2 or higher), past or current clinically significant arrhythmia and/or conduction disorder within 6 months prior to study treatment start - History of thromboembolic or cerebrovascular events within 6 months prior to start of study treatment - Concurrent neuromuscular disorder that is associated with potential elevation of Creatine Kinase - Known contraindication to cetuximab administration as per SPC/approved label

性别

参与研究的性别:

All

年龄

最小年龄：18 Years ，最大年龄：N/A

接受健康的志愿者

没有

可入组国家 ^ICMJE

管理信息

数据检测委员会

Yes

研究涉及美国FDA监管的产品

研究美国FDA监管的药品: Yes
研究涉及美国FDA监管的设备产品: No

IPD 共享声明

计划分享 IPD:

责任方

，

研究赞助商 ^ICMJE

Pierre Fabre Medicament

合作者 ^ICMJE

研究员 ^ICMJE

Study Director: Karim Keddad, MD Pierre Fabre Medicament

PRS 账户

验证日期

October 2018

^ICMJE 国际医学期刊编辑委员会和世界卫生组织 ICTRP 要求的元素

请使用微信扫码报名